Psychedelic-Assissted Therapy for Veterans and Personality Improvement
Psychedelic-assisted therapy at the VA
Psychedelic-assisted therapy has recently gained mainstream acceptance among civilians, but what about for members of the military and veterans?
This therapy may soon be an option for some veterans. As “Lucid” reports, “psychedelic-assisted therapy is on the rise at some veterans administration hospitals.”
Phase 3 clinical trials of MDMA therapy to treat post-traumatic stress disorder have been so successful, with 68 percent of participants in remission, the FDA granted MDMA a special ‘Breakthrough Therapy’ designation. But this therapy is not yet available all over the country, prompting more researchers to call on the VA to create protocols for MDMA, psilocybin, and ketamine therapies. These psychedelics are still classified as Schedule 1 narcotics, and it will take political will and bipartisan support to win FDA approval.
If that happens, researchers at the forefront of these therapies hope to see VA hospitals nationwide using psychedelics to help veterans by the year 2024.
Could the use of hallucinogens actually improve your personality?
A new study published in the journal Frontiers in Psychology looked at how psychedelics affect personality. Researchers recruited adults who were planning on using hallucinogens in the near future and asked them to fill out a survey regarding their personality, based on the five-factor model of personality traits:
- Extraversion
- Neuroticism
- Openness to experience
- Agreeableness
- Conscientiousness
Participants took the survey three times — before their psychedelic experience, two weeks after, and four weeks after. The results were impressive, with people reporting a reduction in neuroticism and an increase in agreeableness, even four weeks after their experience.
Brandon Weiss, a psychologist at Imperial College London and lead researcher told Psychology Today, “[F]irst, people seemed to report that they were not as quarrelsome or critical in their interactions with others. Second, people reported that they were less easily upset by things and less anxious.”
Weiss also pointed out that despite these positive outcomes, hallucinogens can be dangerous, especially with people who have pre-existing psychosis. More data is needed to confirm the studies’ findings. As a large number of participants did not follow through with the entire survey. But this is more evidence that hallucinogens could be another tool to help with mental health.
New Studies Find Psychedelics Highly Effective for Alcoholism
New studies show unprecedented success in the treatment of alcoholism with psychedelic therapy.
The psychedelic revolution in mental health has produced overwhelming scientific evidence demonstrating the great efficacy of psychedelics in the treatment of various mental health disorders. Now, several new studies involving the drugs ketamine and MDMA are showing significant promise in the treatment of alcoholism.
Dr. Ben Sessa is a psychiatrist and chief medical officer at Awakn Life Sciences, an English biotech company that is at the forefront of the research, development, and delivery of psychedelic medicines.
The company is especially focused on the treatment of Alcohol Use Disorder or AUD, given how prevalent and challenging it is to treat.
“Alcoholism is a huge public health problem. It’s also a psychiatric condition that’s very poorly treated with very poor outcomes with traditional methods,” Sessa said. “Relapse to drinking after getting dry is around 80 to 90 percent at 12 months. That’s an embarrassingly poor statistic. Psychedelics offer a completely new approach; they offer the patient to explore the root causes of addiction, which so often is trauma. Psychedelic-assisted psychotherapy is an intensive upfront piece of work that gets the patient better, so they don’t have to keep coming back. It is a completely different paradigm shift to the way we currently manage patients in maintenance therapies.”
A recent study conducted by researchers at the University of Exeter and Awakn Life Sciences is the world’s first to examine the use of ketamine to treat AUD in a randomized controlled trial.
“Ketamine is a very well-established human medicine. It is indeed the only psychedelic that’s licensed as a medicine, as an anesthetic medicine, and has been used since the 60s as such. It’s an incredibly safe medicine. When it’s used at a much lower dose, it produces an altered state of consciousness. What we do in psychedelic-assisted psychotherapy with ketamine, is we use this altered state of consciousness to affect a more effective and deeper form of psychotherapy. So, we’re using ketamine as an adjunct to psychotherapy to treat addictions,” he said.
